Clinical Trial Update: Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating pembrolizumab in combination with vorinostat for recurrent, metastatic, or unresectable squamous cell cancers of the head an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
• Nasopharyngeal Carcinoma
• Salivary Gland Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Zolinza (vorinostat)

Snippet

Sponsor: University of Washington | Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-10-22